Retatrutide (development code LY3437943) is one of the most closely watched compounds in metabolic research. Unlike first-generation GLP peptides that act on a single receptor, retatrutide is a triple-receptor agonist — it engages three separate pathways at once.
The three receptors
- GLP-1 receptor — the pathway behind appetite regulation and glucose-dependent insulin response, the same target as semaglutide.
- GIP receptor — a second incretin pathway that appears to amplify metabolic effects, also targeted by tirzepatide.
- Glucagon receptor — the pathway retatrutide adds on top, associated in research with energy expenditure and lipid metabolism.
Why the third receptor matters
Adding glucagon-receptor activity is the defining feature of retatrutide. In published Phase 2 research, the highest studied doses were associated with the largest reductions in body weight seen to date for this class of compound over the study window. Researchers attribute this partly to the combined incretin effect and the glucagon pathway’s role in energy use.
Take our 60-second quiz for a personalized recommendation and unlock 35% off your first order of USA-made, COA-verified GLP.
Where retatrutide stands today
Retatrutide remains investigational — it has not received regulatory approval and is studied in a research context. That status is exactly why sourcing matters: research-grade material should be backed by a third-party certificate of analysis (COA) confirming identity and purity. You can review batch COAs in our COA library.
To compare retatrutide against semaglutide and tirzepatide side by side, see our GLP peptide comparison, or read how retatrutide works at the receptor level.
For research and educational use only. The information here is not medical advice and RDAmd products are not intended to diagnose, treat, cure, or prevent any disease or for human consumption. Retatrutide is an investigational compound and is not approved by the FDA. Always consult a qualified professional.
